! F3 a% @8 f/ @, @" h. m
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: 5 S% U! d" r! z( Y' F5 K0 YEverolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.9 g; c m. Z0 T http://www.ncbi.nlm.nih.gov/pubmed/22968184% W4 o# l5 @% Z$ Z4 v